HK1251481A1 - 使用白介素-17(il-17)拮抗劑治療放射學陰性中軸型脊柱關節炎的方法 - Google Patents

使用白介素-17(il-17)拮抗劑治療放射學陰性中軸型脊柱關節炎的方法

Info

Publication number
HK1251481A1
HK1251481A1 HK18111096.0A HK18111096A HK1251481A1 HK 1251481 A1 HK1251481 A1 HK 1251481A1 HK 18111096 A HK18111096 A HK 18111096A HK 1251481 A1 HK1251481 A1 HK 1251481A1
Authority
HK
Hong Kong
Prior art keywords
interleukin
antagonists
methods
treating non
axial spondyloarthritis
Prior art date
Application number
HK18111096.0A
Other languages
English (en)
Inventor
Christian Mann
Brian Porter
Hanno Richards
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1251481A1 publication Critical patent/HK1251481A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18111096.0A 2015-10-19 2018-08-29 使用白介素-17(il-17)拮抗劑治療放射學陰性中軸型脊柱關節炎的方法 HK1251481A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562243381P 2015-10-19 2015-10-19

Publications (1)

Publication Number Publication Date
HK1251481A1 true HK1251481A1 (zh) 2019-02-01

Family

ID=57223732

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111096.0A HK1251481A1 (zh) 2015-10-19 2018-08-29 使用白介素-17(il-17)拮抗劑治療放射學陰性中軸型脊柱關節炎的方法

Country Status (11)

Country Link
US (1) US20190330328A1 (zh)
EP (1) EP3365011A1 (zh)
JP (3) JP6858766B2 (zh)
KR (1) KR20180064415A (zh)
CN (1) CN108367074A (zh)
AU (3) AU2016342578A1 (zh)
CA (1) CA3002622A1 (zh)
HK (1) HK1251481A1 (zh)
IL (2) IL297775A (zh)
RU (2) RU2020124276A (zh)
WO (1) WO2017068472A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297775A (en) * 2015-10-19 2022-12-01 Novartis Ag Methods for the treatment of non-radiographic sclerosing spondylitis with the help of interleukin-17 (il-17) antagonists
US11492396B2 (en) 2015-10-27 2022-11-08 UCB Biopharma SRL Methods of treatment using anti-IL-17A/F antibodies
WO2018236728A1 (en) * 2017-06-18 2018-12-27 Kindred Biosciences, Inc. ANTIBODIES AND ANTAGONISTS OF IL17A FOR VETERINARY USE
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
WO2020157305A1 (en) 2019-01-31 2020-08-06 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
US20220222816A1 (en) * 2019-04-29 2022-07-14 UCB Biopharma SRL Medical image analysis system and method for identification of lesions
CN114981302A (zh) * 2019-09-20 2022-08-30 诺华股份有限公司 使用白细胞介素-17(il-17)拮抗剂治疗自身免疫性疾病的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US8012477B2 (en) 2006-01-31 2011-09-06 Novartis Ag Methods of treating multiple myeloma using IL-17 binding molecules
ES2804624T1 (es) * 2010-11-05 2021-02-08 Novartis Ag Métodos de tratamiento de artritis psoriásica usando antagonistas de IL-17
KR20150010709A (ko) * 2012-04-20 2015-01-28 노파르티스 아게 Il-17 길항제를 사용하는 강직성 척추염의 치료 방법
IL297775A (en) * 2015-10-19 2022-12-01 Novartis Ag Methods for the treatment of non-radiographic sclerosing spondylitis with the help of interleukin-17 (il-17) antagonists

Also Published As

Publication number Publication date
IL297775A (en) 2022-12-01
CN108367074A (zh) 2018-08-03
EP3365011A1 (en) 2018-08-29
AU2021240290A1 (en) 2021-11-11
US20190330328A1 (en) 2019-10-31
JP2021100956A (ja) 2021-07-08
AU2016342578A1 (en) 2018-03-29
JP2023134701A (ja) 2023-09-27
RU2018118177A3 (zh) 2020-02-17
CA3002622A1 (en) 2017-04-27
IL257723B2 (en) 2023-04-01
RU2018118177A (ru) 2019-11-21
JP7389077B2 (ja) 2023-11-29
JP2018537418A (ja) 2018-12-20
WO2017068472A1 (en) 2017-04-27
KR20180064415A (ko) 2018-06-14
RU2020124276A (ru) 2021-08-03
IL257723A (en) 2018-04-30
IL257723B (en) 2022-12-01
RU2728710C2 (ru) 2020-07-30
RU2020124276A3 (zh) 2022-01-18
JP6858766B2 (ja) 2021-04-14
AU2019240551A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗劑治療放射學陰性中軸型脊柱關節炎的方法
HK1248552A1 (zh) 使用川地匹坦的治療方法
IL252296A0 (en) Methods for treating multiple sclerosis
GB201514760D0 (en) Compounds and method of use
IL256207B (en) Methods for treating multiple sclerosis
GB201507188D0 (en) Resilient unit and method of manufacture
HK1247818A1 (zh) 治療疾病的方法
EP3684342C0 (en) TREATMENT PROCEDURES
GB201706406D0 (en) Method of treatment
HK1255221A1 (zh) 使用卡多曲組合物進行治療的方法
GB201815588D0 (en) Method of treatment
GB201604627D0 (en) Improved method of FT-IMS
GB2553390B (en) Method of manufacture
GB201609170D0 (en) Method of manufacture
IL274214A (en) A method for treating tendinitis using interleukin-17 (IL-17) antagonists
GB201602802D0 (en) Method of treatment
HK1243937A1 (zh) 治療疾病的方法
GB201613971D0 (en) Method of manufacture
GB201609171D0 (en) Method of manufacture
SG11201706066RA (en) Method of producing substance
SG11201710199PA (en) Methods of treating multiple sclerosis
GB201704816D0 (en) Method of manufacture
GB201512139D0 (en) Methods of treatment
GB2567222B (en) Method of manufacture
GB201720439D0 (en) Method of treatment